[ T able_StockInfo] 2025 年 03 月 24 日 证券研究报告•2024 年年报点评 华特达因（000915）医药生物 目标价：36.48 元（6 个月） 买入 （维持） 当前价：28.64 元 深耕儿童用药，新产品研发稳步推进 | 指标/年度 | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业收入（百万元） | 2134.49 | 2344.15 | 2597.84 | 2905.04 | | 增长率 | -14.08% | 9.82% | 10.82% | 11.83% | | 归属母公司净利润（百万元） | 515.59 | 533.18 | 559.66 | 633.55 | | 增长率 | -11.90% | 3.41% | 4.97% | 13.20% | | 每股收益 EPS（元） | 2.20 | 2.28 | 2.39 | 2.70 | | 净资产收益率 ROE | 22.80% | 20.96% | 19.85% | 19.99% | | PE | 13 | 13 | 12 | ...

[ T able_StockInfo] 2025 年 03 月 24 日 证券研究报告•2024 年年报点评 巨星农牧（603477）农林牧渔 目标价：23.55 元（6 个月） 买入 （维持） 当前价：19.49 元 生猪业务驱动业绩反转，成本控制与产能扩张构筑成长动能 | [Table_MainProfit] 指标/年度 | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业收入（百万元） | 6,078 | 8,153 | 10,494 | 12,546 | | 增长率 | 50.43% | 34.13% | 28.72% | 19.55% | | 归属母公司净利润（百万元） | 519 | 802 | 1,108 | 1,441 | | 增长率 | 180.36% | 54.73% | 38.06% | 30.09% | | 每股收益 EPS（元） | 1.02 | 1.57 | 2.17 | 2.83 | | 净资产收益率 ROE | 15.71% | 19.56% | 21.26% | 21.67% | | PE ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of —— yuan over the next six months [1] Core Views - The company continues to upgrade its product structure and is making steady progress in national expansion [1] - The company achieved a revenue of 30.21 billion yuan in 2024, representing a year-on-year growth of 18.6%, and a net profit of 3.88 billion yuan, also up by 18.0% [7] - The growth momentum for high-end products priced above 300 yuan remains strong, with significant sales increases in key product lines [7] - The company is focusing on marketing transformation and actively cultivating consumer bases in both domestic and provincial markets [7] Financial Summary - **Revenue Forecast**: Expected revenues for 2025, 2026, and 2027 are 32.86 billion yuan, 36.31 billion yuan, and 40.65 billion yuan respectively, with growth rates of 8.75%, 10.51%, and 11.95% [2] - **Net Profit Forecast**: Projected net profits for the same years are 4.11 billion yuan, 4.62 billion yuan, and 5.32 billion yuan, with growth rates of 5.91%, 12.40%, and 15.04% [2] - **Earnings Per Share (EPS)**: EPS is expected to be 0.81 yuan in 2025, 0.91 yuan in 2026, and 1.05 yuan in 2027 [2] - **Return on Equity (ROE)**: ROE is projected to increase from 11.48% in 2024 to 12.56% in 2027 [2] Product and Market Analysis - **Product Segmentation**: Revenue from products priced above 300 yuan, between 100-300 yuan, and below 100 yuan for 2024 was 5.7 billion yuan, 14.9 billion yuan, and 8.5 billion yuan respectively, with growth rates of 41.2%, 15.4%, and 4.0% [7] - **Regional Performance**: Revenue from within the province was 22.3 billion yuan, up 16.1%, while revenue from outside the province was 6.7 billion yuan, up 14.7% [7] - **Cost and Profitability**: The gross margin for 2024 was 60.9%, a decrease of 1.5 percentage points year-on-year, attributed to increased promotional activities [7] Strategic Outlook - The company is actively pursuing a strategy of national expansion while deepening its market presence in the northwest region [7] - The focus on high-end products is expected to drive growth, with a clear path for future development [7]

从财报角度看眼科公司成长路径 (更新至2024Q3) 西南证券研究院 2025年3月 分析师：杜向阳 执业证号：S1250520030002 电话：021-68416017 邮箱：duxy@swsc.com.cn 分析师：汪翌雯 执业证号：S1250522120002 邮箱：wangyw@swsc.com.cn 投资要点 行业：眼科医疗服务市场规模持续增长 眼科医疗行业维持双位数增长。中国眼科医疗服务市场的行业规模从2015年507.1亿增长至2024年的2231亿元，持续维持增 长。其中，根据2023年数据，民营医院同比增长率达31%, 公立医院同比增长率达10%，预计2025年中国眼科医疗服务市场规 模达到2521.5亿元，2020-2025年年复合增长率为16.0%，中国眼科医疗市场持续扩容确定性高。 业务：屈光量价齐升、白内障人工晶体量增价降 公司：一超多强格局形成，扩张下沉各显神通 相关标的 1 屈光量价齐升、仪器推动全飞秒占比提升。根据各公司招股书披露数据，屈光项目实现量价齐升，华厦眼科屈光手术平均客单 价从2019年的8680.7元/眼提升至2021年的8922.5元/眼，中高端术式占比由201 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 18.60 CNY over the next six months, while the current price is 12.85 CNY [1]. Core Views - The company's growth is driven by three main factors: scale effects, international expansion, and the development of a pet medical ecosystem [1]. - The company has seen rapid growth in its export business, with exports increasing from 3.78 million CNY in 2020 to 33.34 million CNY in the first half of 2024, and the Vietnam factory is expected to start production in Q2 2025 [2]. - The introduction of new pet medications and the integration of the industry chain are expected to create a second growth curve for the company [2]. Summary by Sections Company Overview - The company, established in January 2002, focuses on animal health, integrating R&D, production, and sales, and is a leading player in the veterinary drug industry [12]. - The main business segments include veterinary drug formulations, raw materials, and pet medical services, with significant market presence in both domestic and international markets [12]. Industry Analysis - The veterinary drug industry in China is experiencing growth, with the market size increasing from 484 billion CNY in 2017 to 673 billion CNY in 2022, reflecting a CAGR of 6.1% [21]. - The industry is currently at a cyclical low, but the demand for veterinary products is expected to rise as the livestock sector recovers [28]. Research and Innovation - The company emphasizes R&D, with over 1.7 billion CNY invested from 2021 to Q3 2024, and a growing team of over 180 researchers [44]. - The integration of raw material production and drug formulation is expected to lower costs and improve profitability [44]. Financial Forecast and Valuation - Revenue is projected to grow from 1,020 million CNY in 2023 to 1,936 million CNY by 2026, with a significant increase in net profit expected in 2025 [8]. - The company is expected to achieve an EPS of 0.93 CNY in 2025, with a corresponding PE ratio of 13.85 [8].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for the next six months [1]. Core Views - The company is experiencing a recovery in the industry with multiple rounds of price increases, demonstrating strong growth resilience [1]. - The company achieved a total revenue of 158.56 billion yuan in 2024, reflecting a year-on-year growth of 6.59%, while the net profit attributable to the parent company was 24.45 billion yuan, down 19.70% year-on-year [7][10]. - The company plans to distribute a cash dividend of 2.4 yuan per 10 shares, with a cash dividend ratio of 39.3% [7]. Financial Performance Summary - **Revenue and Profit Forecasts**: - Revenue is projected to grow from 158.56 billion yuan in 2024 to 223.63 billion yuan by 2027, with growth rates of 6.59%, 14.18%, 12.16%, and 10.13% respectively [3][10]. - Net profit is expected to increase from 24.45 billion yuan in 2024 to 38.50 billion yuan in 2027, with growth rates of -19.70%, 8.20%, 24.54%, and 16.86% respectively [3][10]. - **Earnings Per Share (EPS)**: - EPS is forecasted to rise from 0.61 yuan in 2024 to 0.96 yuan in 2027 [3][10]. - **Return on Equity (ROE)**: - ROE is expected to improve from 8.04% in 2024 to 10.27% in 2027 [3][10]. - **Valuation Metrics**: - Price-to-Earnings (PE) ratio is projected to decrease from 21 in 2024 to 13 in 2027, indicating an improving valuation as earnings grow [3][10]. - Price-to-Book (PB) ratio is expected to decline from 1.71 in 2024 to 1.39 in 2027 [3][10]. Market Position and Competitive Advantage - The company maintains a leading position in the fiberglass industry, with significant scale advantages and a focus on high-end product development [7][10]. - The company has achieved the world's largest production capacity in several product categories, reinforcing its competitive edge [7][10]. - The report highlights the company's commitment to innovation and R&D, which has led to the development of proprietary technologies and products that are at the forefront of the industry [7][10].

[ T able_StockInfo] 2025 年 03 月 20 日 证券研究报告•2024 年年报点评 牧原股份（002714）农林牧渔 目标价：46.15 元（6 个月） 买入 （维持） 当前价：38.26 元 24 年生猪业务量价齐增，成本控制成效显著 | [Table_MainProfit] 指标/年度 | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业收入（百万元） | 137,947 | 146,239 | 160,822 | 176,860 | | 增长率 | 24.43% | 6.01% | 9.97% | 9.97% | | 归属母公司净利润（百万元） | 17,881 | 19,394 | 24,399 | 31,820 | | 增长率 | 519.42% | 8.46% | 25.81% | 30.41% | | 每股收益 EPS（元） | 3.30 | 3.55 | 4.47 | 5.82 | | 净资产收益率 ROE | 24.82% | 21.39% | 21.20% | 21.66% | ...

[ T able_StockInfo] 2025 年 03 月 19 日 证券研究报告•2024 年年报点评 福耀玻璃（600660）汽车 目标价：——元（6 个月） 买入 （维持） 当前价：57.51 元 高附加值产品占比提升，ASP 持续增长 | [Table_MainProfit] 指标/年度 | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业收入（亿元） | 392.52 | 456.45 | 521.79 | 591.43 | | 增长率 | 18.37% | 16.29% | 14.32% | 13.35% | | 归属母公司净利润（亿元） | 74.98 | 87.78 | 101.35 | 115.68 | | 增长率 | 33.20% | 17.07% | 15.46% | 14.14% | | 每股收益 EPS（元） | 2.87 | 3.36 | 3.88 | 4.43 | | 净资产收益率 ROE | 21.03% | 22.56% | 23.58% | 24.28% | | PE | 20 | ...

Investment Rating - The report maintains a "Buy" rating for Youyou Food (603697) with a target price of —— yuan over the next six months [1][3]. Core Insights - The company achieved a revenue of 1.182 billion yuan in 2024, representing a year-on-year growth of 22.4%, and a net profit attributable to the parent company of 157.33 million yuan, up 35.4% year-on-year. The fourth quarter of 2024 saw a revenue of 290 million yuan, a 42.9% increase year-on-year, and a net profit of 36 million yuan, a remarkable 258% growth year-on-year [7][10]. - The company plans to distribute a cash dividend of 2.10 yuan per 10 shares (including tax), resulting in an overall cash dividend payout ratio of 127.77% for 2024 [7]. - The growth in revenue is driven by strong performance in emerging channels, with online and offline channel revenue growth rates of 204% and 17.7%, respectively [7][8]. - The company is expanding its presence in new retail channels, particularly in the East China region, which has shown rapid growth due to the expansion of emerging channels and increased marketing efforts [7][8]. Summary by Sections Financial Performance - For 2024, the company reported total revenue of 1,182.33 million yuan and a net profit of 157.33 million yuan. The projected revenues for 2025, 2026, and 2027 are 1,480.06 million yuan, 1,712.14 million yuan, and 1,950.61 million yuan, respectively, with growth rates of 25.18%, 15.68%, and 13.93% [2][10]. - The earnings per share (EPS) are expected to increase from 0.37 yuan in 2024 to 0.70 yuan by 2027, with corresponding price-to-earnings (PE) ratios decreasing from 27 to 14 over the same period [2][10]. Business Segments - The revenue from various product lines in 2024 includes 784.6 million yuan from spicy chicken feet, 158.5 million yuan from other flavored meat products, and 93.3 million yuan from skin products, with significant growth rates in each category [8][10]. - The company anticipates continued strong performance in its core products, particularly in the spicy chicken feet segment, which is expected to maintain a growth rate of 12.3% in 2025 [8]. Cost and Profitability - The overall gross margin for 2024 was 29%, with a slight decrease of 0.4 percentage points year-on-year. However, the gross margin for Q4 2024 improved to 25.7%, reflecting better cost management and efficiency [7][10]. - The net profit margin for 2024 increased by 1.3 percentage points to 13.3%, driven by cost reductions and improved operational efficiency [7][10].

[ T able_StockInfo] 2025 年 03 月 20 日 证券研究报告•2024 年业绩快报点评 国药一致（000028）医药生物 目标价：33.18 元（6 个月） 买入 （维持） 当前价：26.27 元 商誉减值致短期承压，2025 年经营有望改善 | 指标/年度 | 2023A | 2024E | 2025E | 2026E | | --- | --- | --- | --- | --- | | 营业收入（百万元） | 75477.48 | 74378.49 | 78097.42 | 83564.24 | | 增长率 | 2.77% | -1.46% | 5.00% | 7.00% | | 归属母公司净利润（百万元） | 1599.26 | 642.49 | 1318.46 | 1492.62 | | 增长率 | 7.57% | -59.83% | 105.21% | 13.21% | | 每股收益 EPS（元） | 2.87 | 1.15 | 2.37 | 2.68 | | 净资产收益率 ROE | 9.34% | 3.91% | 7.03% | 7.48% | | PE | 9 | ...